Holen Sie sich die Stockscreener-App
99.11
4.29%
4.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$94.97
Offen:
$95.48
24-Stunden-Volumen:
7.75M
Relative Volume:
0.63
Marktkapitalisierung:
$246.09B
Einnahmen:
$63.90B
Nettoeinkommen (Verlust:
$19.05B
KGV:
13.11
EPS:
7.5596
Netto-Cashflow:
$13.05B
1W Leistung:
+6.59%
1M Leistung:
+13.04%
6M Leistung:
+28.67%
1J Leistung:
-0.81%
1-Tages-Spanne:
$95.36
$99.28
1-Wochen-Bereich:
$92.11
$99.28
52-Wochen-Spanne:
$73.31
$105.07
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
99.15 | 235.72B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
LLY
Lilly Eli Co
|
1,060.06 | 933.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.26 | 489.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
236.91 | 405.53B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
127.78 | 238.62B | 54.45B | 14.42B | 17.15B | 7.333 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains - Benzinga
Merck & Co., Inc. $MRK Shares Bought by Willis Investment Counsel - MarketBeat
Swiss National Bank Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Personal CFO Solutions LLC Sells 28,729 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Holdings Lowered by Handelsbanken Fonder AB - MarketBeat
Primecap Management Co. CA Sells 5,600 Shares of Merck & Co., Inc. $MRK - MarketBeat
FY2025 EPS Estimate for Merck & Co., Inc. Raised by Analyst - MarketBeat
24,341 Shares in Merck & Co., Inc. $MRK Purchased by CFC Planning Co LLC - MarketBeat
DNB Asset Management AS Sells 3,000 Shares of Merck & Co., Inc. $MRK - MarketBeat
The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock - Zacks Investment Research
Top Analyst Reports for Visa, Merck & Southern Company - TradingView
Prudential PLC Buys 56,360 Shares of Merck & Co., Inc. $MRK - MarketBeat
TD Waterhouse Canada Inc. Trims Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK is FUKOKU MUTUAL LIFE INSURANCE Co's 9th Largest Position - MarketBeat
Ensign Peak Advisors Inc Purchases 536,384 Shares of Merck & Co., Inc. $MRK - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 4,920 Shares of Merck & Co., Inc. $MRK - MarketBeat
Artisan Partners Limited Partnership Sells 26,500 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck’s Two-Drug HIV Regimen Matches Gilead’s Three-Drug TabletMerck & Co (NYSE:MRK) - Benzinga
Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial - Reuters
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study - TradingView
Merck & Co., Inc. (MRK) Stock: European Union Approves Subcutaneous Keytruda - CoinCentral
Merck & Co., Inc. (NYSE:MRK) Plans Dividend Increase$0.85 Per Share - MarketBeat
Traub Capital Management LLC Purchases New Holdings in Merck & Co., Inc. $MRK - MarketBeat
TSP Capital Management Group LLC Purchases 6,100 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck gets EU nod for subcutaneous version of Keytruda (MRK:NYSE) - Seeking Alpha
Stonebrook Private Inc. Sells 31,083 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Heritage Wealth Advisors - MarketBeat
Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial - Seeking Alpha
Jefferies Adjusts Price Target on Merck & Co. to $139 From $138, Maintains Buy Rating - MarketScreener
ARS Investment Partners LLC Trims Position in Merck & Co., Inc. $MRK - MarketBeat
Merck (NYSE:MRK) in Focus as Healthcare Indices Shift Direction - Kalkine Media
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything - Finviz
Vanguard Group Inc. Buys 401,045 Shares of Merck & Co., Inc. $MRK - MarketBeat
WBI Investments LLC Buys 8,548 Shares of Merck & Co., Inc. $MRK - MarketBeat
Deutsche Bank Aktiengesellschaft Raises Merck & Co., Inc. (NYSE:MRK) Price Target to $111.00 - MarketBeat
Merck & Co, Amer Sports among market cap stock movers on Tuesday - Investing.com
Merck & Co., Inc. (NYSE:MRK) Shares Up 3.6%Still a Buy? - MarketBeat
Merck’s Winrevair Success Expands Beyond Pulmonary HypertensionMerck & Co (NYSE:MRK) - Benzinga
Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio - ts2.tech
Merck Announces First-Quarter 2026 Dividend - FinancialContent
Merck, Bristol announce additional layoffs in New Jersey - Seeking Alpha
Merck posts trial win for Winrevair in new indication (MRK) - Seeking Alpha
Merck & Co., Inc. $MRK Shares Acquired by Invenio Wealth Partners LLC - MarketBeat
Nordwand Advisors LLC Acquires 43,951 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck (NYSE: MRK) Reports WINREVAIR PVR Reduction in Phase 2 CADENCE HFpEF Study - Stock Titan
Frank Rimerman Advisors LLC Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Cordatus Wealth Management LLC Sells 9,760 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stake Lessened by Empowered Funds LLC - MarketBeat
Merck Has Many Bullish Attributes (Technical Analysis) - Seeking Alpha
Merck Buys Cidara In $9.2 Billion Deal—Here’s What They’re Really After! - Smartkarma
Merck sees over $5 billion opportunity in Cidara's experimental flu drug - Reuters
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):